Novel paracellin-1 mutations in 25 families with familial hypomagnesemia with hypercalciuria and nephrocalcinosis
Language English Country United States Media print
Document type Journal Article, Research Support, Non-U.S. Gov't
PubMed
11518780
DOI
10.1681/asn.v1291872
PII: 12/9/1872
Knihovny.cz E-resources
- MeSH
- Child MeSH
- Phenotype MeSH
- Genotype MeSH
- Magnesium blood MeSH
- Claudins MeSH
- Cohort Studies MeSH
- Infant MeSH
- Kidney physiopathology MeSH
- Humans MeSH
- Membrane Proteins genetics MeSH
- Adolescent MeSH
- Molecular Sequence Data MeSH
- Mutation genetics MeSH
- Nephrocalcinosis genetics metabolism physiopathology MeSH
- Child, Preschool MeSH
- Pedigree MeSH
- Amino Acid Sequence genetics MeSH
- Calcium urine MeSH
- Check Tag
- Child MeSH
- Infant MeSH
- Humans MeSH
- Adolescent MeSH
- Male MeSH
- Child, Preschool MeSH
- Female MeSH
- Publication type
- Journal Article MeSH
- Research Support, Non-U.S. Gov't MeSH
- Names of Substances
- claudin 16 MeSH Browser
- Magnesium MeSH
- Claudins MeSH
- Membrane Proteins MeSH
- Calcium MeSH
Familial hypomagnesemia with hypercalciuria and nephrocalcinosis (FHHNC) is an autosomal recessive tubular disorder that is frequently associated with progressive renal failure. The primary defect is related to impaired tubular reabsorption of magnesium and calcium in the thick ascending limb of Henle's loop. Mutations in PCLN-1, which encodes the renal tight junction protein paracellin-1 (claudin-16), were identified as the underlying genetic defects. Comprehensive clinical data and the results of PCLN-1 mutation analysis of 25 FHHNC families with 33 affected individuals are presented. Patients presented mainly with urinary tract infections, polyuria, and hematuria at a median age of 3.5 yr. At the time of diagnosis, the GFR was already decreased to <60 ml/min per 1.73 m(2) for 11 patients. Twelve patients exhibited progression to end-stage renal disease, at a median age of 14.5 yr. Treatment with magnesium salts and thiazides seemed to have no effect on the progression of the disease. Genotype analysis revealed PCLN-1 mutations in all except three mutant alleles (94%). Fifteen different mutations were observed, including eight novel mutations. The accumulation of mutations affecting the first extracellular loop was striking, with 48% of all mutant alleles exhibiting a Leu151Phe exchange. Haplotype analysis strongly suggested a founder effect among patients with FHHNC who originated from Germany or eastern European countries. In 13 of 23 families, hypercalciuria and/or nephrolithiasis were observed in otherwise unaffected family members, indicating a possible role of heterozygous PCLN-1 mutations in yielding hypercalciuric stone-forming conditions.
Clinic for Children's Diseases Skopje Macedonia
Department of Pediatrics Philipps University Marburg Germany
Department of Pediatrics University Hospital Clermont Ferrand France
Department of Pediatrics University Hospital Erlangen Germany
Department of Pediatrics University Hospital Essen Germany
Department of Pediatrics University Hospital Heidelberg Germany
Department of Pediatrics University Hospital Jena Germany
Department of Pediatrics University Hospital Maribor Slovenia
Department of Pediatrics University Hospital Münster Germany
Department of Pediatrics University Hospital Ostrava Czech Republic
Department of Pediatrics University Hospital Prague Czech Republic
References provided by Crossref.org